Pain Therapeutics is a Solid Pick in Biotech Industry Pain Therapeutics is working in the biotech and pharmaceutical industry, having a business sector capitalization of $116.69 million. Opioid misuse is a developing pestilence, and the […]

Palatin Technologies Inc. (PTN) Palatin Technologies Inc. (PTN ) has been moving recently as the stock has ascended by 19% in the previous four weeks, and it is as of now exchanging great over its […]

Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) It’s been an unpleasant year for Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) shareholders. PPHM slammed on 2/26/2016 when the organization’s Phase III trial for Bavituximab (an exploratory hostile to malignancy medication) was ended. […]

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) An oral insulin tablet could tackle, however for a long time, no organization has made sense of how to even hypothetically regulate insulin orally. That is, as of recently. Oramed Pharmaceuticals, […]

Northwest Biotherapeutics (NWBO) Following a decline of 9.3% amid Northwest Biotherapeutics (NWBO) facilitates all things considered volume in light of its revelation that it reduced the activity costs for certain warrant holders as an instigation […]

MiMedx Group Inc (MDXG) MiMedx Group Inc (MDXG) shares exchanged higher after the organization reported strong growth in its second quarter and increased its full year guidance. The organization said that in light of the […]

Marinus Pharmaceuticals, Inc. (MRNS) Marinus Pharmaceuticals, Inc. (MRNS ) was a major mover recently, as its shares ascended more than 29%. The move went ahead strong volume too with significantly a greater number of shares […]

Mast Therapeutics (NYSEMKT:MSTX) Mast Therapeutics (NYSEMKT:MSTX) says stage 3 EPIC trial of vepoloxamer, which treats people with sickle cell illness encountering vaso-occlusive emergency, did not meet its essential adequacy endpoint. Endpoint was measurably huge diminishment […]

Is Aurinia’s Share Price Undervalued? On August 16, 2016, Aurinia’s share price had dove in spite of its Phase 2B study meeting the essential endpoints in the treatment of Lupus Nephritis with Aurinia’s lead drug […]

IMMUNOMEDICS, INC. (IMMU) IMMUNOMEDICS, INC. (IMMU) got agreement suggestion of “Beat” from Analysts surveyed at Thomson Reuters. The Company anticipated that would declare next income roughly $-0.13 for each share. One Month Ago Analyst Ratings: […]